Optimierung der Vitamin-D3 Aufnahme in der Krebstherapie

Pathways out of tumor-induced vitamin D resistance. In this scientific presentation from the iQMedix Therapists' Congress 2026, Dr. Alexander Michalzik explains why an adequate vitamin D level alone is not enough – and what role the vitamin D receptor (VDR) plays as a nuclear transcription factor in the oncological context. The focus is on epidemiological data on 25(OH)D serum levels and cancer incidence, the calcitriol-VDR signaling pathway, the modulation of key tumor signaling pathways (WNT, NF-κB, EMT), and how tumors specifically suppress the VDR axis – and which bioactive substances such as curcumin, resveratrol, butyrate, and sulforaphane can contribute to its reactivation. This presentation is aimed at therapists interested in molecular oncology and complementary approaches. 🔬 Learn more about molecular tumor diagnostics via liquid biopsy: 👉 www.iQMedix.eu Disclaimer: The medical content presented in this video is for general information and educational purposes only. iQMedix GmbH is a provider of molecular diagnostic services and not a healthcare provider in the sense of medical practice. The content does not replace a medical diagnosis, individual medical advice, or treatment. It is not suitable as a basis for independent diagnosis, treatment decisions, or changes to previously recommended treatments. The completeness, accuracy, or timeliness of the information presented is not guaranteed. Please always consult your doctor with any health-related questions or concerns. utm_source=youtube&utm_medium=video&utm_campaign=therapeutenkongress2026&utm_content=michalzik_vitamind